Life Sciences-Specific CRM Now Provides Complete Single Platform that Brings Multichannel Together, Empowering Better Customer Interactions
ROME - Friday, June 6th 2014 [ME NewsWire]
(BUSINESS WIRE)-- Cegedim Relationship Management today announced the availability of the latest release of its Life Sciences-specific Customer Relationship Management (CRM) platform, Mobile Intelligence, which features a groundbreaking, complete, single platform that brings multichannel together, empowering Life Sciences teams to create better customer interactions. The announcement was made at Cegedim’s annual customer conference in Rome, where Life Sciences leaders have gathered in a spirit of co-creation to explore the advances in technology that make their businesses run more efficiently.
Executing a Multichannel Strategy for Comprehensive Customer Engagement
As the healthcare industry continues to evolve and increase in complexity considering multiple stakeholders, more specialized markets, increasing regulation and budgetary restrictions, Life Sciences customer-facing organizations seek a more efficient way to collaborate that adds value and respects compliance. The need for multichannel customer engagement becomes imperative to maintain effective customer relationships. Mobile Intelligence, a versatile solution that fits multiple situations, offers Life Sciences companies the capability to coordinate the execution of a multichannel strategy that differentiates them from competitors, and helps them reach more and better outcomes.
Mobile Intelligence blasts the boundaries of traditional CRM, as companies know it, because it enables multichannel to become actionable by providing the widest range of channels from a single platform of engagement. In addition to the channels existing in previous releases of Mobile Intelligence, including face-to-face, sampling, closed loop marketing (CLM), meetings, congresses and contact center, Mobile Intelligence now supports fast growing channels.
Remote interactions capabilities - online and through the iPad*
Secured Messaging - compliant e-mails for field and customer facing teams
Enhanced CLM to provide further flexibility to field users
Social CRM enablement, including customer centric collaboration leveraging Yammer and Lync** integration
Paperless event management
“Mobile Intelligence 10 offers the widest and unmatched set of channels natively integrated with multi stakeholder data and insights,” explained Laurent Labrune, Chief Executive Officer of Cegedim Relationship Management. “This enables each customer facing team to collaborate to execute their multichannel engagement strategy, using cross functional mobile solutions adapted to their needs. In so doing, they maintain their presence and access to target populations, despite budgetary restrictions, engaging customers in an efficient and compliant way.”
The Cegedim CRM solution helps Life Sciences companies transition from the traditional face-to-face customer engagement strategy, to an orchestrated multichannel engagement program which identifies customers across multiple communication channels; ensures a coherent message across channels; and finds the right channel mix adapted to each customer.
Other key enhancements to Mobile Intelligence include: offline coaching capabilities for district managers; mobile order entry for retail support; and direct access to Cegedim’s OneKey® healthcare professional (HCP) / healthcare organization (HCO) database, with new embedded analytic capabilities.
* iPad is a trademark of Apple Inc. ** Yammer is a trademark of Yammer, Inc., and Lync is a trademark of Microsoft Corporation.
About Cegedim Relationship Management:
Cegedim Relationship Management is the Life Sciences industry’s leading provider of Customer Relationship Management (CRM) solutions. Designed specifically for Life Sciences, the company’s innovative business solutions incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Relationship Management enables approximately 200,000 users in many of the world’s most innovative companies to stay ahead of market challenges. In addition to CRM, Cegedim Relationship Management also provides marketing, data optimization and regulatory compliance solutions in more than 80 countries. Cegedim Relationship Management is part of the France-based Cegedim S.A. Group.
To learn more, please visit: www.cegedim.com/rm. Follow Cegedim Relationship Management on LinkedIn and Twitter.
About Cegedim:
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,000 people in more than 80 countries and generated revenue of €902 million in 2013. Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit: www.cegedim.com. Follow Cegedim on Twitter: @CegedimGroup.
Contacts
Cegedim Relationship Management
Drew BUSTOS
Global Communications
Tel.: +1 (908) 443.2451
drew.bustos@cegedim.com
Cegedim
Aude BALLEYDIER
Media Relations
Tel.: +33 (0)1 49 09 68 81
aude.balleydier@cegedim.fr
Permalink: http://www.me-newswire.net/news/11232/en
Sunday, June 8, 2014
New Study Reported Prevena™ Therapy Patients Had a Significantly Lower Infection Rate Following Cardiac Surgery Compared to Control Group
Surgical incision management could generate savings of more than 60 million Euros in Germany alone
SAN ANTONIO. - Wednesday, June 4th 2014 [ME NewsWire]
(BUSINESS WIRE) Kinetic Concepts, Inc. announced today that a new study, published in the International Wound Journal, showed the Prevena™ Incision Management System used over closed incisions for the first six to seven days reported a significantly lower infection rate than conventional dressings in patients undergoing cardiac surgery via median sternotomy. Post-sternotomy wound infection is a serious, potentially fatal complication of cardiac surgery which often requires additional surgery, and is associated with significantly increased health care costs.
This study compared the infection rates of 3,745 patients who had received median sternotomy for cardiac surgery; 237 patients received surgical incision management via the Prevena™ System (-125mmHg) for six to seven days, and the remaining 3,508 were given conventional sterile wound tape dressings. After 30 days, only three (1.3%) of the 237 patients in the Prevena™ Therapy group had wound infections, while 119 (3.4%) of the 3,508 patients in the conventional dressing group had infections at the incision site (p<0.05; odds ratio 2.74).
“This study showed that use of the Prevena™ System led to a statistically significant reduction in infection rates of all patients following median sternotomy,” said Prof. Onnen Grauhan, Senior Physician, Deutsches Herzzentrum Berlin, Germany. “In my practice, utilizing surgical incision management is an effective therapy that reduces the likelihood of postoperative wound infection. This therapy provides a potential savings of 60 million to 90 million Euros per year in Germany.”
The Deutsches Herzzentrum Berlin is an internationally renowned high-performance hospital for the treatment of cardiovascular and thoracic diseases, performing over 4,500 major cardiovascular surgeries per year.
“To date, this is the largest clinical study demonstrating the effectiveness of Prevena™ Therapy,” said Ron Silverman, MD, chief medical officer, KCI. “It adds to the growing body of evidence that supports the use of Prevena™ Therapy over closed surgical incisions. This study is particularly interesting in that it looked at all patients receiving sternotomy, rather than a particular high risk subgroup as in previous studies.” (O Grauhan, et al. Prevention of post-sternotomy wound infections in obese patients by negative pressure wound therapy. J Thorac Cardiovasc Surg 2012 October 27.)
The Prevena™ Incision Management System is intended to manage closed surgical incisions. Prevena™ Therapy is an example of continuing efforts by KCI to change the practice of medicine with solutions that can help speed healing, reduce complications and improve the lives of patients.
“Prevena™ Therapy is truly transforming how surgical incisions are managed, thereby expanding our surgical solution platform,” said Joe Woody, president & CEO, KCI. “This highlights the opportunity to expand our full suite of negative pressure wound therapy products into different or adjacent procedures that serve as a key area for growth, providing substantial clinical and economic benefit to our customers and patients.”
About KCI
Kinetic Concepts, Inc. (KCI) is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 75 countries around the world. KCI, along with LifeCell Corporation and Systagenix Wound Management, form one globally diversified wound care, biologics and regenerative medicine company, committed to advancing the science of medicine to reduce complications, speed healing and improve patient lives. Headquartered in San Antonio, Texas, the company is a leader in the medical technology industry with the most comprehensive offering of best-in-class surgical and chronic wound therapies. Additional information about KCI and its products is available at www.KCI1.com.
Contacts
KCI Corporate Communications
Mike Barger, +1-210-255-6824
mike.barger@kci1.com
KCI Investor Relations
Nathan Speicher, +1-210-255-6027
nathan.speicher@kci1.com
Permalink: http://me-newswire.net/news/11207/en
SAN ANTONIO. - Wednesday, June 4th 2014 [ME NewsWire]
(BUSINESS WIRE) Kinetic Concepts, Inc. announced today that a new study, published in the International Wound Journal, showed the Prevena™ Incision Management System used over closed incisions for the first six to seven days reported a significantly lower infection rate than conventional dressings in patients undergoing cardiac surgery via median sternotomy. Post-sternotomy wound infection is a serious, potentially fatal complication of cardiac surgery which often requires additional surgery, and is associated with significantly increased health care costs.
This study compared the infection rates of 3,745 patients who had received median sternotomy for cardiac surgery; 237 patients received surgical incision management via the Prevena™ System (-125mmHg) for six to seven days, and the remaining 3,508 were given conventional sterile wound tape dressings. After 30 days, only three (1.3%) of the 237 patients in the Prevena™ Therapy group had wound infections, while 119 (3.4%) of the 3,508 patients in the conventional dressing group had infections at the incision site (p<0.05; odds ratio 2.74).
“This study showed that use of the Prevena™ System led to a statistically significant reduction in infection rates of all patients following median sternotomy,” said Prof. Onnen Grauhan, Senior Physician, Deutsches Herzzentrum Berlin, Germany. “In my practice, utilizing surgical incision management is an effective therapy that reduces the likelihood of postoperative wound infection. This therapy provides a potential savings of 60 million to 90 million Euros per year in Germany.”
The Deutsches Herzzentrum Berlin is an internationally renowned high-performance hospital for the treatment of cardiovascular and thoracic diseases, performing over 4,500 major cardiovascular surgeries per year.
“To date, this is the largest clinical study demonstrating the effectiveness of Prevena™ Therapy,” said Ron Silverman, MD, chief medical officer, KCI. “It adds to the growing body of evidence that supports the use of Prevena™ Therapy over closed surgical incisions. This study is particularly interesting in that it looked at all patients receiving sternotomy, rather than a particular high risk subgroup as in previous studies.” (O Grauhan, et al. Prevention of post-sternotomy wound infections in obese patients by negative pressure wound therapy. J Thorac Cardiovasc Surg 2012 October 27.)
The Prevena™ Incision Management System is intended to manage closed surgical incisions. Prevena™ Therapy is an example of continuing efforts by KCI to change the practice of medicine with solutions that can help speed healing, reduce complications and improve the lives of patients.
“Prevena™ Therapy is truly transforming how surgical incisions are managed, thereby expanding our surgical solution platform,” said Joe Woody, president & CEO, KCI. “This highlights the opportunity to expand our full suite of negative pressure wound therapy products into different or adjacent procedures that serve as a key area for growth, providing substantial clinical and economic benefit to our customers and patients.”
About KCI
Kinetic Concepts, Inc. (KCI) is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 75 countries around the world. KCI, along with LifeCell Corporation and Systagenix Wound Management, form one globally diversified wound care, biologics and regenerative medicine company, committed to advancing the science of medicine to reduce complications, speed healing and improve patient lives. Headquartered in San Antonio, Texas, the company is a leader in the medical technology industry with the most comprehensive offering of best-in-class surgical and chronic wound therapies. Additional information about KCI and its products is available at www.KCI1.com.
Contacts
KCI Corporate Communications
Mike Barger, +1-210-255-6824
mike.barger@kci1.com
KCI Investor Relations
Nathan Speicher, +1-210-255-6027
nathan.speicher@kci1.com
Permalink: http://me-newswire.net/news/11207/en
Posted by
Business Daily Africa
Saturday, June 7, 2014
Neymar Jr Scores the Toughest and Most Unusual 'Goal' of His Career
See It Through His Own Eyes Thanks to the Panasonic A500 Wearable 4K Camera
OSAKA, Japan - Thursday, June 5th 2014 [ME NewsWire]
(BUSINESS WIRE)-- Panasonic has teamed up with Brazilian football superstar, Neymar da Silva Santos Junior, to
promote its latest 4K wearable camera, the A500.
Panasonic asked Neymar Jr to wear a prototype of its A500 wearable 4K camera and challenged him to score the
hardest ‘goal’ of his career!
Panasonic today released 4K/30P footage taken by the A500 from Neymar Jr’s very own perspective as he took on
the challenge. To discover if he succeeded or not – and to see exclusive behind the scenes footage – take a look at
the YouTube video, entitled “Neymar’s Eye” located at http://youtu.be/C0vo5B92GgI.
About the A500
Panasonic’s HX-A500 is the world’s first 4K/30p (25p) Wearable Camera and enables you to shoot scenes that put
viewers right there, in the thick of the action.
The main unit is separate from the lens unit, meaning you can mount the lens at face level and carry out hands-free
shooting. Small and lightweight, the lens unit is comfortable to wear, making it easy to shoot casual sports action or
to capture the expressions of your family at play.
HX-A500 features gorgeous 4K/30p (25p) image quality, allowing you to capture beautiful images with heightened
realism. With new Lens, the new BSI sensor and Crystal Engine Pro+, you can now enjoy clean and clear low-noise
images. HX-A500 comes as standard with the newly designed main unit with an LCD and other features that
improves operability. Via your smartphone or tablet, you can also quickly and easily upload your video to the Web.
About Panasonic
Panasonic Corporation is a worldwide leader in the development and engineering of electronic technologies and
solutions for customers in residential, non-residential, mobility and personal applications. Since its founding in
1918, the company has expanded globally and now operates over 500 consolidated companies worldwide,
recording consolidated net sales of 7.74 trillion yen for the year ended March 31, 2014. Committed to pursuing new
value through innovation across divisional lines, the company strives to create a better life and a better world for
its customers. For more information about Panasonic, please visit the company's website at
http://www.panasonic.com/.
Related Link:Panasonic Neymar Jr. Official Pages
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50879577&lang=en
Contacts
Panasonic Corporation
Global Communication Group
Public Relations Office
+81-3-3574-5729
presscontact@ml.jp.panasonic.com
Permalink: http://www.me-newswire.net/news/11225/en
OSAKA, Japan - Thursday, June 5th 2014 [ME NewsWire]
(BUSINESS WIRE)-- Panasonic has teamed up with Brazilian football superstar, Neymar da Silva Santos Junior, to
promote its latest 4K wearable camera, the A500.
Panasonic asked Neymar Jr to wear a prototype of its A500 wearable 4K camera and challenged him to score the
hardest ‘goal’ of his career!
Panasonic today released 4K/30P footage taken by the A500 from Neymar Jr’s very own perspective as he took on
the challenge. To discover if he succeeded or not – and to see exclusive behind the scenes footage – take a look at
the YouTube video, entitled “Neymar’s Eye” located at http://youtu.be/C0vo5B92GgI.
About the A500
Panasonic’s HX-A500 is the world’s first 4K/30p (25p) Wearable Camera and enables you to shoot scenes that put
viewers right there, in the thick of the action.
The main unit is separate from the lens unit, meaning you can mount the lens at face level and carry out hands-free
shooting. Small and lightweight, the lens unit is comfortable to wear, making it easy to shoot casual sports action or
to capture the expressions of your family at play.
HX-A500 features gorgeous 4K/30p (25p) image quality, allowing you to capture beautiful images with heightened
realism. With new Lens, the new BSI sensor and Crystal Engine Pro+, you can now enjoy clean and clear low-noise
images. HX-A500 comes as standard with the newly designed main unit with an LCD and other features that
improves operability. Via your smartphone or tablet, you can also quickly and easily upload your video to the Web.
About Panasonic
Panasonic Corporation is a worldwide leader in the development and engineering of electronic technologies and
solutions for customers in residential, non-residential, mobility and personal applications. Since its founding in
1918, the company has expanded globally and now operates over 500 consolidated companies worldwide,
recording consolidated net sales of 7.74 trillion yen for the year ended March 31, 2014. Committed to pursuing new
value through innovation across divisional lines, the company strives to create a better life and a better world for
its customers. For more information about Panasonic, please visit the company's website at
http://www.panasonic.com/.
Related Link:Panasonic Neymar Jr. Official Pages
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50879577&lang=en
Contacts
Panasonic Corporation
Global Communication Group
Public Relations Office
+81-3-3574-5729
presscontact@ml.jp.panasonic.com
Permalink: http://www.me-newswire.net/news/11225/en
Posted by
Business Daily Africa
Rimini Street Signs More Than 100 SAP Clients To Date, Announces 64-Percent Increase in SAP Support Revenues
SAP Licensees Leveraging Independent Support to Drive Rapid, Cost-Effective Innovation into Their SAP Landscape
ME NewsWire/Business Wire
ORLANDO, Fla. - Wednesday, June 4th 2014
SAPPHIRE NOW 2014
SAPPHIRE NOW 2014 Conference -- Rimini Street, Inc., the leading independent provider of enterprise software support for SAP AG’s (NYSE: SAP) Business Suite and BusinessObjects software and Oracle Corporation’s (NYSE: ORCL) Siebel, PeopleSoft, JD Edwards, E-Business Suite, Oracle Database, Oracle Middleware, Hyperion and Oracle Retail software, today announced continued year-over-year growth and client success for its SAP support product line. Annual revenue for Rimini Street support for SAP applications increased by 64.4 percent for the 12-month period ending March 31, 2014, compared to the prior 12 months, with more than 100 total clients to date who have switched from SAP to Rimini Street support. Beyond the significant cost savings achieved by switching to Rimini Street, including up to 90 percent on total support costs over a decade and an immediate 50 percent reduction of annual support fees, SAP licensees are choosing Rimini Street to enable their IT Innovation strategy.
Rimini Street Helps SAP Licensees Drive Innovation Now
Successful IT landscapes are transforming from large, integrated single-vendor product suites to a hybrid IT landscape of core transaction “systems of record” integrated with best-of-breed software applications, and include a combination of on-premise and cloud application delivery models. Rimini Street provides comprehensive support for mission-critical SAP core transaction systems while enabling clients to flexibly and cost-effectively integrate cloud solutions into their current SAP landscape.
Southco Adopts Hybrid IT Landscape with Help from Rimini Street
When leading international manufacturer Southco switched from SAP to Rimini Street independent support in 2009, it immediately cut its second-highest IT expense in half. Since then, the company has completed successful rollouts in many countries as part of its strategic SAP global expansion efforts while using Rimini Street for support of its SAP ECC 6.0 system.
Southco redirected a portion of its substantial annual maintenance cost savings from using Rimini Street to purchase new licenses from Salesforce.com and SuccessFactors to address its global CRM and HCM infrastructure needs in the cloud. Rimini Street provided support for Southco’s SAP applications through the transition and continued with support for the company’s remaining extensive SAP landscape as part of its Rimini Street Cloud Services offering.
“With the independent support we received from Rimini Street, Southco was able to invest in cloud-based solutions like Salesforce.com and SuccessFactors while keeping our IT budget flat,” said Patrik Larsson, Manager of SAP Global Support at Southco. “This has enabled Southco to adopt cloud solutions in conjunction with our existing SAP system in a hybrid model that best suits our business-driven innovation needs.”
Color Spot Expands SAP Footprint While Supported by Rimini Street
Color Spot Nurseries, a leading specialty horticulture producer and distributor, switched from SAP support to Rimini Street support for its SAP system in 2010. The company was able to improve its support, cut its annual vendor maintenance costs down from 20 percent to only nine percent of the total IT budget, and more than double their discretionary IT budget. Since then, Color Spot has purchased and deployed new SAP licenses to keep up with its aggressive growth strategy and relied on Rimini Street for support of its expanding SAP footprint.
By choosing independent support, Color Spot realized additional benefits, including an assigned Primary Support Engineer (PSE) available 24x7x365 that eliminates the need for extra maintenance resources and headcount; responsive support with a guaranteed response time of 30 minutes or less; and premium-level services, including support for customizations at no additional cost. Adding to their significant cost savings, Color Spot also was able to avoid a costly and unnecessary forced upgrade for the sake of staying supported, as well as guaranteed support for a minimum of 15 years for existing releases without required upgrades.
“With independent support, Color Spot is in the driver’s seat when it comes to our SAP software roadmap,” said Eric Robinson, Color Spot CIO. “Beyond the substantial cost savings and great improvement in service levels, my team is now helping drive bottom line growth by redirecting our annual software maintenance cost savings and freed up resources towards critical new solutions for our business teams.”
Rimini Street Helps SAP Licensees Worldwide Drive Innovation
Rimini Street began providing independent support for SAP more than four years ago. Since then, more than 100 licensees, including Fortune 500 and Fortune 100 companies, across a wide range of industries and with operations in over 70 countries have switched from SAP to Rimini Street for independent support of their SAP systems. In addition to achieving significant savings, many SAP licensees who switched to Rimini Street Support have funded innovative projects and business initiatives that drive competitive edge, while gaining improved, premium service features, including support for customizations at no additional cost.
“More than 100 companies from around the world, ranging from Fortune 500 to midmarket companies, have already made the switch to Rimini Street for support of their complex, mission-critical SAP systems,” said Seth Ravin, Rimini Street CEO. “And like Color Spot and Southco, these savvy companies are using Rimini Street independent support to maximize the value of their SAP software maintenance dollars and reallocate IT budgets and resources to fund innovation in strategic areas of the business.”
About Rimini Street, Inc.
Rimini Street is the leading independent provider of enterprise software support services. The company is redefining enterprise support services with an innovative, award-winning program that enables Oracle and SAP licensees to save up to 90 percent on total support costs over a decade, including saving 50 percent on their annual support fees. Clients can remain on their current software release without any required upgrades or migrations for at least 15 years after switching to Rimini Street. Hundreds of clients, including global, Fortune 500, midmarket, and public sector organizations from across a broad range of industries have selected Rimini Street as their trusted, independent support provider. To learn more, please visit www.riministreet.com or call within the USA 888-870-9692 or internationally +1 702-839-9671.
Rimini Street and the Rimini Street logo are trademarks of Rimini Street, Inc. All other company and product names may be trademarks of their respective owners. Copyright © 2014. All rights reserved.
Contacts
Rimini Street, Inc.
Alma Park, +1 323-229-7282
apark@riministreet.com
Permalink: http://www.me-newswire.net/news/11203/en
ME NewsWire/Business Wire
ORLANDO, Fla. - Wednesday, June 4th 2014
SAPPHIRE NOW 2014
SAPPHIRE NOW 2014 Conference -- Rimini Street, Inc., the leading independent provider of enterprise software support for SAP AG’s (NYSE: SAP) Business Suite and BusinessObjects software and Oracle Corporation’s (NYSE: ORCL) Siebel, PeopleSoft, JD Edwards, E-Business Suite, Oracle Database, Oracle Middleware, Hyperion and Oracle Retail software, today announced continued year-over-year growth and client success for its SAP support product line. Annual revenue for Rimini Street support for SAP applications increased by 64.4 percent for the 12-month period ending March 31, 2014, compared to the prior 12 months, with more than 100 total clients to date who have switched from SAP to Rimini Street support. Beyond the significant cost savings achieved by switching to Rimini Street, including up to 90 percent on total support costs over a decade and an immediate 50 percent reduction of annual support fees, SAP licensees are choosing Rimini Street to enable their IT Innovation strategy.
Rimini Street Helps SAP Licensees Drive Innovation Now
Successful IT landscapes are transforming from large, integrated single-vendor product suites to a hybrid IT landscape of core transaction “systems of record” integrated with best-of-breed software applications, and include a combination of on-premise and cloud application delivery models. Rimini Street provides comprehensive support for mission-critical SAP core transaction systems while enabling clients to flexibly and cost-effectively integrate cloud solutions into their current SAP landscape.
Southco Adopts Hybrid IT Landscape with Help from Rimini Street
When leading international manufacturer Southco switched from SAP to Rimini Street independent support in 2009, it immediately cut its second-highest IT expense in half. Since then, the company has completed successful rollouts in many countries as part of its strategic SAP global expansion efforts while using Rimini Street for support of its SAP ECC 6.0 system.
Southco redirected a portion of its substantial annual maintenance cost savings from using Rimini Street to purchase new licenses from Salesforce.com and SuccessFactors to address its global CRM and HCM infrastructure needs in the cloud. Rimini Street provided support for Southco’s SAP applications through the transition and continued with support for the company’s remaining extensive SAP landscape as part of its Rimini Street Cloud Services offering.
“With the independent support we received from Rimini Street, Southco was able to invest in cloud-based solutions like Salesforce.com and SuccessFactors while keeping our IT budget flat,” said Patrik Larsson, Manager of SAP Global Support at Southco. “This has enabled Southco to adopt cloud solutions in conjunction with our existing SAP system in a hybrid model that best suits our business-driven innovation needs.”
Color Spot Expands SAP Footprint While Supported by Rimini Street
Color Spot Nurseries, a leading specialty horticulture producer and distributor, switched from SAP support to Rimini Street support for its SAP system in 2010. The company was able to improve its support, cut its annual vendor maintenance costs down from 20 percent to only nine percent of the total IT budget, and more than double their discretionary IT budget. Since then, Color Spot has purchased and deployed new SAP licenses to keep up with its aggressive growth strategy and relied on Rimini Street for support of its expanding SAP footprint.
By choosing independent support, Color Spot realized additional benefits, including an assigned Primary Support Engineer (PSE) available 24x7x365 that eliminates the need for extra maintenance resources and headcount; responsive support with a guaranteed response time of 30 minutes or less; and premium-level services, including support for customizations at no additional cost. Adding to their significant cost savings, Color Spot also was able to avoid a costly and unnecessary forced upgrade for the sake of staying supported, as well as guaranteed support for a minimum of 15 years for existing releases without required upgrades.
“With independent support, Color Spot is in the driver’s seat when it comes to our SAP software roadmap,” said Eric Robinson, Color Spot CIO. “Beyond the substantial cost savings and great improvement in service levels, my team is now helping drive bottom line growth by redirecting our annual software maintenance cost savings and freed up resources towards critical new solutions for our business teams.”
Rimini Street Helps SAP Licensees Worldwide Drive Innovation
Rimini Street began providing independent support for SAP more than four years ago. Since then, more than 100 licensees, including Fortune 500 and Fortune 100 companies, across a wide range of industries and with operations in over 70 countries have switched from SAP to Rimini Street for independent support of their SAP systems. In addition to achieving significant savings, many SAP licensees who switched to Rimini Street Support have funded innovative projects and business initiatives that drive competitive edge, while gaining improved, premium service features, including support for customizations at no additional cost.
“More than 100 companies from around the world, ranging from Fortune 500 to midmarket companies, have already made the switch to Rimini Street for support of their complex, mission-critical SAP systems,” said Seth Ravin, Rimini Street CEO. “And like Color Spot and Southco, these savvy companies are using Rimini Street independent support to maximize the value of their SAP software maintenance dollars and reallocate IT budgets and resources to fund innovation in strategic areas of the business.”
About Rimini Street, Inc.
Rimini Street is the leading independent provider of enterprise software support services. The company is redefining enterprise support services with an innovative, award-winning program that enables Oracle and SAP licensees to save up to 90 percent on total support costs over a decade, including saving 50 percent on their annual support fees. Clients can remain on their current software release without any required upgrades or migrations for at least 15 years after switching to Rimini Street. Hundreds of clients, including global, Fortune 500, midmarket, and public sector organizations from across a broad range of industries have selected Rimini Street as their trusted, independent support provider. To learn more, please visit www.riministreet.com or call within the USA 888-870-9692 or internationally +1 702-839-9671.
Rimini Street and the Rimini Street logo are trademarks of Rimini Street, Inc. All other company and product names may be trademarks of their respective owners. Copyright © 2014. All rights reserved.
Contacts
Rimini Street, Inc.
Alma Park, +1 323-229-7282
apark@riministreet.com
Permalink: http://www.me-newswire.net/news/11203/en
Posted by
Business Daily Africa
EMA Accepts Marketing Authorisation Application for Nintedanib in IPF
INGELHEIM, Germany. - Thursday, June 5th 2014 [ME NewsWire]
Acceptance of marketing authorisation application marks the beginning of regulatory review process for nintedanib* in IPF in EU
EMA has accepted the request for accelerated assessment
Application for nintedanib* in IPF is supported by pivotal data from two replicate Phase III trials involving more than 1,000 patients
Data show that nintedanib* consistently slows disease progression by reducing annual decline in lung function by half
(BUSINESS WIRE) For non-US health media only
Boehringer Ingelheim today announced that the application for marketing authorisation of nintedanib*, a tyrosine kinase inhibitor (TKI), for the treatment of idiopathic pulmonary fibrosis (IPF) has been validated and granted accelerated assessment by the European Medicines Agency (EMA).The acceptance of this marketing authorisation application marks the beginning of the review process in the European Union for this potential new treatment.
“IPF is a relentless and fatal lung disease and there is a high unmet need for effective treatments that can slow disease progression,” said Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “Acceptance of our marketing authorisation application takes us one step closer to meeting this unmet need and providing a new treatment option to patients living with IPF.”
The marketing authorisation application for nintedanib* included results from two Phase III trials with identical design, INPULSIS™-1 and INPULSIS™-2, which showed nintedanib* significantly slowed disease progression in patients with IPF. Data from the two 52-week trials, recently published in the New England Journal of Medicine, demonstrate that nintedanib* met the primary endpoint by significantly reducing the annual decline in forced vital capacity by approximately 50% compared to patients taking placebo.1 This effect on disease progression was further supported in the pooled data set by a positive signal in reducing the risk of acute exacerbations by 38% (p=0.08) and a significant risk reduction in confirmed or suspected acute exacerbations by 68% (p=0.005).
Nintedanib*, two capsules a day, is the first targeted treatment for IPF that has consistently demonstrated to slow disease progression in IPF by significantly reducing the decline in lung function by half with a manageable side effect profile.
Boehringer Ingelheim is committed to making nintedanib* available to patients with IPF and is prepared to respond to requests for compassionate use, subject to local regulations.
*Nintedanib is an investigational compound. Its safety and efficacy have not yet been fully established.
~ENDS~
Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/05_june_2014_ipf.html
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Linda Calandra
Phone: +49 1511 502-1148
Fax: +49 (6132) 77-6601
Email: press@boehringeringelheim.com
Permalink: http://www.me-newswire.net/news/11222/en
Acceptance of marketing authorisation application marks the beginning of regulatory review process for nintedanib* in IPF in EU
EMA has accepted the request for accelerated assessment
Application for nintedanib* in IPF is supported by pivotal data from two replicate Phase III trials involving more than 1,000 patients
Data show that nintedanib* consistently slows disease progression by reducing annual decline in lung function by half
(BUSINESS WIRE) For non-US health media only
Boehringer Ingelheim today announced that the application for marketing authorisation of nintedanib*, a tyrosine kinase inhibitor (TKI), for the treatment of idiopathic pulmonary fibrosis (IPF) has been validated and granted accelerated assessment by the European Medicines Agency (EMA).The acceptance of this marketing authorisation application marks the beginning of the review process in the European Union for this potential new treatment.
“IPF is a relentless and fatal lung disease and there is a high unmet need for effective treatments that can slow disease progression,” said Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “Acceptance of our marketing authorisation application takes us one step closer to meeting this unmet need and providing a new treatment option to patients living with IPF.”
The marketing authorisation application for nintedanib* included results from two Phase III trials with identical design, INPULSIS™-1 and INPULSIS™-2, which showed nintedanib* significantly slowed disease progression in patients with IPF. Data from the two 52-week trials, recently published in the New England Journal of Medicine, demonstrate that nintedanib* met the primary endpoint by significantly reducing the annual decline in forced vital capacity by approximately 50% compared to patients taking placebo.1 This effect on disease progression was further supported in the pooled data set by a positive signal in reducing the risk of acute exacerbations by 38% (p=0.08) and a significant risk reduction in confirmed or suspected acute exacerbations by 68% (p=0.005).
Nintedanib*, two capsules a day, is the first targeted treatment for IPF that has consistently demonstrated to slow disease progression in IPF by significantly reducing the decline in lung function by half with a manageable side effect profile.
Boehringer Ingelheim is committed to making nintedanib* available to patients with IPF and is prepared to respond to requests for compassionate use, subject to local regulations.
*Nintedanib is an investigational compound. Its safety and efficacy have not yet been fully established.
~ENDS~
Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/05_june_2014_ipf.html
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Linda Calandra
Phone: +49 1511 502-1148
Fax: +49 (6132) 77-6601
Email: press@boehringeringelheim.com
Permalink: http://www.me-newswire.net/news/11222/en
Posted by
Business Daily Africa
Quintiles Executive to Present at the 2014 Wells Fargo Healthcare Conference
Wells Fargo Healthcare Conference 2014
RESEARCH TRIANGLE PARK, N.C. - Thursday, June 5th 2014 [ME NewsWire]
(BUSINESS WIRE)-- Quintiles CFO Kevin Gordon will present at the 2014 Wells Fargo Healthcare Conference on Tuesday, June 17, 2014, in Boston’s InterContinental Hotel.
The Quintiles presentation will begin at 1:10 p.m. EDT. Investors may access a live audio webcast of the presentation on the Quintiles investor relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day.
About Quintiles
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 29,000 employees conducting business in approximately 100 countries. We helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Phil Bridges, Media Relations (phil.bridges@quintiles.com)
+ 1.919.998.1653 (office) +1.919.457.6347 (mobile)
Karl Deonanan, Investor Relations (InvestorRelations@quintiles.com)
+1.919.998.2789
Permalink: http://www.me-newswire.net/news/11230/en
RESEARCH TRIANGLE PARK, N.C. - Thursday, June 5th 2014 [ME NewsWire]
(BUSINESS WIRE)-- Quintiles CFO Kevin Gordon will present at the 2014 Wells Fargo Healthcare Conference on Tuesday, June 17, 2014, in Boston’s InterContinental Hotel.
The Quintiles presentation will begin at 1:10 p.m. EDT. Investors may access a live audio webcast of the presentation on the Quintiles investor relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day.
About Quintiles
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 29,000 employees conducting business in approximately 100 countries. We helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Phil Bridges, Media Relations (phil.bridges@quintiles.com)
+ 1.919.998.1653 (office) +1.919.457.6347 (mobile)
Karl Deonanan, Investor Relations (InvestorRelations@quintiles.com)
+1.919.998.2789
Permalink: http://www.me-newswire.net/news/11230/en
Posted by
Business Daily Africa
Pradaxa gains EU Approval for Treatment and Prevention of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism
INGELHEIM, Germany. - Friday, June 6th 2014 [ME NewsWire]
Pradaxa® is a simple treatment option that is as effective as warfarin with significantly lower bleeding rates, a major advance for DVT and PE patients1–4
EU approval follows recent U.S. FDA approval of Pradaxa® in DVT and PE and increases access to a treatment with proven protective benefits1–5
New approval makes Pradaxa® one of the most broadly indicated novel oral anticoagulants1,6,7
For media outside of the U.S., the UK & Canada only
(BUSINESS WIRE) Boehringer Ingelheim today announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).1 The U.S. Food and Drug Administration (FDA) approved Pradaxa® for DVT and PE patients earlier this year.5 DVT and PE can be very dangerous; almost one in three PE patients dies within three months and four out of 10 patients suffer a repeat blood clot within 10 years of the first.8,9
“We are delighted with the European Commission’s decision to approve Pradaxa® for DVT and PE patients, confirming the well-studied efficacy and safety profile of Pradaxa®, which has been established in a clinical trial programme in close to 10,000 patients for DVT and PE, and over 40,000 patients across different indications,” commented Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “Access to this new treatment option is critical for patients as we know that PE as a consequence of a DVT is still the leading cause of preventable death in hospital.”
The approval by the European Commission follows the positive opinion issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency, and is based on results from three robust phase III clinical trials that demonstrated the efficacy of Pradaxa® in the treatment and prevention of repeat DVT and PE compared to warfarin.2–4 In a fourth trial, data showed a 92% reduction in the risk of recurrent blood clots in patients treated with Pradaxa® compared to placebo.4 With regards to safety, results showed that DVT or PE patients taking Pradaxa® experienced significantly lower rates of bleeding than those taking warfarin, resulting in a favourable overall safety profile.2–4 Pradaxa® has the longest clinical trial experience in DVT and PE patients of any novel oral anticoagulant (NOAC).4, 10–15
“This approval for dabigatran is a major advance for DVT and PE patients and their physicians,” said Professor Dr. Stavros Konstantinides, Deputy Scientific Director of the Centre for Thrombosis and Haemostasis of Johannes Gutenberg University, Mainz, Germany. “Clinical trial results show that dabigatran has a favourable safety profile compared to warfarin, while offering similar efficacy for the treatment and prevention of recurrence of DVT and PE. The added benefits of convenience and a simple fixed dose regimen will appeal to patients and their physicians alike.”
Pradaxa® is convenient for patients as it does not require routine dose monitoring, nor a mandatory dose change during the course of treatment. DVT and PE patients can start taking Pradaxa® in a simple fixed dose regimen after initial treatment with an injectable anticoagulant such as low-molecular-weight heparin (LMWH). 1
Clinical experience of Pradaxa® equates to over 2.9 million patient-years in all licensed indications worldwide. 16 Pradaxa® has already been available for more than six years and is approved in over 100 countries to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).1,16 Pradaxa® 150mg bid is the only NOAC, study of which (RE-LY®) has shown a significant reduction in the incidence of both ischaemic and haemorrhagic strokes versus warfarin in patients with NVAF.17,18 Ischaemic strokes, which account for nine out of 10 strokes experienced by patients with AF, can have devastating consequences and are often fatal or severely disabling.19,20 RE-LY® was a global, phase III, PROBE (prospective, randomized, open-label with blinded endpoint evaluation) design trial comparing two fixed doses of the oral direct thrombin inhibitor Pradaxa® (110mg and 150mg bid) each administered in a blinded manner, with open label warfarin.17,18,21 Pradaxa® 110mg bid, which is indicated for certain patients, showed non-inferior efficacy versus warfarin for reducing risk of stroke.1,17,18 Pradaxa® is also approved for primary prevention of VTE (venous thromboembolism, the collective term for DVT and PE) in patients who have undergone elective total hip or total knee replacement surgery.1
~ENDS~
Please click on the link below for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/06_june_2014_dabigatranetexilate.html
Contacts
Boehringer Ingelheim GmbH
Friederike Middeke
Phone: +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
Email: press@boehringer-ingelheim.com
Twitter: http://twitter.com/Boehringer
More information
www.boehringer-ingelheim.com
Permalink: http://www.me-newswire.net/news/11242/en
Pradaxa® is a simple treatment option that is as effective as warfarin with significantly lower bleeding rates, a major advance for DVT and PE patients1–4
EU approval follows recent U.S. FDA approval of Pradaxa® in DVT and PE and increases access to a treatment with proven protective benefits1–5
New approval makes Pradaxa® one of the most broadly indicated novel oral anticoagulants1,6,7
For media outside of the U.S., the UK & Canada only
(BUSINESS WIRE) Boehringer Ingelheim today announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).1 The U.S. Food and Drug Administration (FDA) approved Pradaxa® for DVT and PE patients earlier this year.5 DVT and PE can be very dangerous; almost one in three PE patients dies within three months and four out of 10 patients suffer a repeat blood clot within 10 years of the first.8,9
“We are delighted with the European Commission’s decision to approve Pradaxa® for DVT and PE patients, confirming the well-studied efficacy and safety profile of Pradaxa®, which has been established in a clinical trial programme in close to 10,000 patients for DVT and PE, and over 40,000 patients across different indications,” commented Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “Access to this new treatment option is critical for patients as we know that PE as a consequence of a DVT is still the leading cause of preventable death in hospital.”
The approval by the European Commission follows the positive opinion issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency, and is based on results from three robust phase III clinical trials that demonstrated the efficacy of Pradaxa® in the treatment and prevention of repeat DVT and PE compared to warfarin.2–4 In a fourth trial, data showed a 92% reduction in the risk of recurrent blood clots in patients treated with Pradaxa® compared to placebo.4 With regards to safety, results showed that DVT or PE patients taking Pradaxa® experienced significantly lower rates of bleeding than those taking warfarin, resulting in a favourable overall safety profile.2–4 Pradaxa® has the longest clinical trial experience in DVT and PE patients of any novel oral anticoagulant (NOAC).4, 10–15
“This approval for dabigatran is a major advance for DVT and PE patients and their physicians,” said Professor Dr. Stavros Konstantinides, Deputy Scientific Director of the Centre for Thrombosis and Haemostasis of Johannes Gutenberg University, Mainz, Germany. “Clinical trial results show that dabigatran has a favourable safety profile compared to warfarin, while offering similar efficacy for the treatment and prevention of recurrence of DVT and PE. The added benefits of convenience and a simple fixed dose regimen will appeal to patients and their physicians alike.”
Pradaxa® is convenient for patients as it does not require routine dose monitoring, nor a mandatory dose change during the course of treatment. DVT and PE patients can start taking Pradaxa® in a simple fixed dose regimen after initial treatment with an injectable anticoagulant such as low-molecular-weight heparin (LMWH). 1
Clinical experience of Pradaxa® equates to over 2.9 million patient-years in all licensed indications worldwide. 16 Pradaxa® has already been available for more than six years and is approved in over 100 countries to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).1,16 Pradaxa® 150mg bid is the only NOAC, study of which (RE-LY®) has shown a significant reduction in the incidence of both ischaemic and haemorrhagic strokes versus warfarin in patients with NVAF.17,18 Ischaemic strokes, which account for nine out of 10 strokes experienced by patients with AF, can have devastating consequences and are often fatal or severely disabling.19,20 RE-LY® was a global, phase III, PROBE (prospective, randomized, open-label with blinded endpoint evaluation) design trial comparing two fixed doses of the oral direct thrombin inhibitor Pradaxa® (110mg and 150mg bid) each administered in a blinded manner, with open label warfarin.17,18,21 Pradaxa® 110mg bid, which is indicated for certain patients, showed non-inferior efficacy versus warfarin for reducing risk of stroke.1,17,18 Pradaxa® is also approved for primary prevention of VTE (venous thromboembolism, the collective term for DVT and PE) in patients who have undergone elective total hip or total knee replacement surgery.1
~ENDS~
Please click on the link below for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/06_june_2014_dabigatranetexilate.html
Contacts
Boehringer Ingelheim GmbH
Friederike Middeke
Phone: +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
Email: press@boehringer-ingelheim.com
Twitter: http://twitter.com/Boehringer
More information
www.boehringer-ingelheim.com
Permalink: http://www.me-newswire.net/news/11242/en
Posted by
Business Daily Africa
Subscribe to:
Posts (Atom)